ROCKVILLE, Md. & SHANGHAI–(BUSINESS WIRE)–20/20 GeneSystems, Inc. (www.2020gene.com) (“20/20”) released this week in China what is believed to be the world’s first machine learning algorithm commercialized for use in conjunction with blood tests to aid in the early detection of lung cancer. The cloud accessible software, marketed in China by MyBioMed, Ltd. (www.My-Biomed.com) (“MBM”) is expected to be utilized over the next six months by at least 20 hospitals in five or more cities to help in distinguishing between benign vs. malignant pulmonary nodules following CT imaging.

 

Read the complete article here.